Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer

We herein report the case of a 79-year-old patient with unresectable stage III non-small cell lung cancer who developed immune-related hepatitis caused by durvalumab administration. Durvalumab was administered at 10 mg/kg every two weeks after the treatment with carboplatin (AUC2), paclitaxel (35 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Masakatsu, Otsuka, Toshimi, Hayashi, Ranji, Horita, Tomoe, Ota, Masafumi, Sakurai, Naoko, Takano, Hikaru, Hayashi, Tasuku, Kumagai, Motona, Yamada, Sohsuke, Arisawa, Tomiyasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691038/
https://www.ncbi.nlm.nih.gov/pubmed/32669493
http://dx.doi.org/10.2169/internalmedicine.4699-20
_version_ 1783614203567800320
author Nakamura, Masakatsu
Otsuka, Toshimi
Hayashi, Ranji
Horita, Tomoe
Ota, Masafumi
Sakurai, Naoko
Takano, Hikaru
Hayashi, Tasuku
Kumagai, Motona
Yamada, Sohsuke
Arisawa, Tomiyasu
author_facet Nakamura, Masakatsu
Otsuka, Toshimi
Hayashi, Ranji
Horita, Tomoe
Ota, Masafumi
Sakurai, Naoko
Takano, Hikaru
Hayashi, Tasuku
Kumagai, Motona
Yamada, Sohsuke
Arisawa, Tomiyasu
author_sort Nakamura, Masakatsu
collection PubMed
description We herein report the case of a 79-year-old patient with unresectable stage III non-small cell lung cancer who developed immune-related hepatitis caused by durvalumab administration. Durvalumab was administered at 10 mg/kg every two weeks after the treatment with carboplatin (AUC2), paclitaxel (35 mg/m(2)), and 60 Gy radiation. At the day 208 in which the 14th durvalumab administration was scheduled, the patient was urgently hospitalized due to CTCAE Grade 4 hepatic dysfunction detected during the an outpatient blood sampling test. He was diagnosed with immune-related hepatitis and started on methylprednisolone 60 mg/day. After 51 days, his liver dysfunction improved and he was discharged.
format Online
Article
Text
id pubmed-7691038
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-76910382020-12-03 Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer Nakamura, Masakatsu Otsuka, Toshimi Hayashi, Ranji Horita, Tomoe Ota, Masafumi Sakurai, Naoko Takano, Hikaru Hayashi, Tasuku Kumagai, Motona Yamada, Sohsuke Arisawa, Tomiyasu Intern Med Case Report We herein report the case of a 79-year-old patient with unresectable stage III non-small cell lung cancer who developed immune-related hepatitis caused by durvalumab administration. Durvalumab was administered at 10 mg/kg every two weeks after the treatment with carboplatin (AUC2), paclitaxel (35 mg/m(2)), and 60 Gy radiation. At the day 208 in which the 14th durvalumab administration was scheduled, the patient was urgently hospitalized due to CTCAE Grade 4 hepatic dysfunction detected during the an outpatient blood sampling test. He was diagnosed with immune-related hepatitis and started on methylprednisolone 60 mg/day. After 51 days, his liver dysfunction improved and he was discharged. The Japanese Society of Internal Medicine 2020-07-14 2020-11-01 /pmc/articles/PMC7691038/ /pubmed/32669493 http://dx.doi.org/10.2169/internalmedicine.4699-20 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Nakamura, Masakatsu
Otsuka, Toshimi
Hayashi, Ranji
Horita, Tomoe
Ota, Masafumi
Sakurai, Naoko
Takano, Hikaru
Hayashi, Tasuku
Kumagai, Motona
Yamada, Sohsuke
Arisawa, Tomiyasu
Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer
title Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer
title_full Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer
title_fullStr Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer
title_full_unstemmed Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer
title_short Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer
title_sort durvalumab-induced immune-related hepatitis in a patient with non-small cell lung cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691038/
https://www.ncbi.nlm.nih.gov/pubmed/32669493
http://dx.doi.org/10.2169/internalmedicine.4699-20
work_keys_str_mv AT nakamuramasakatsu durvalumabinducedimmunerelatedhepatitisinapatientwithnonsmallcelllungcancer
AT otsukatoshimi durvalumabinducedimmunerelatedhepatitisinapatientwithnonsmallcelllungcancer
AT hayashiranji durvalumabinducedimmunerelatedhepatitisinapatientwithnonsmallcelllungcancer
AT horitatomoe durvalumabinducedimmunerelatedhepatitisinapatientwithnonsmallcelllungcancer
AT otamasafumi durvalumabinducedimmunerelatedhepatitisinapatientwithnonsmallcelllungcancer
AT sakurainaoko durvalumabinducedimmunerelatedhepatitisinapatientwithnonsmallcelllungcancer
AT takanohikaru durvalumabinducedimmunerelatedhepatitisinapatientwithnonsmallcelllungcancer
AT hayashitasuku durvalumabinducedimmunerelatedhepatitisinapatientwithnonsmallcelllungcancer
AT kumagaimotona durvalumabinducedimmunerelatedhepatitisinapatientwithnonsmallcelllungcancer
AT yamadasohsuke durvalumabinducedimmunerelatedhepatitisinapatientwithnonsmallcelllungcancer
AT arisawatomiyasu durvalumabinducedimmunerelatedhepatitisinapatientwithnonsmallcelllungcancer

Ejemplares similares